Reference : Nuclear Factor-Kappa B, Cancer, and Apoptosis
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/18485
Nuclear Factor-Kappa B, Cancer, and Apoptosis
English
Bours, Vincent mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Génétique générale et humaine]
Bentires-Alj, M. [> > > >]
Hellin, A. C. [> > > >]
Viatour, Patrick [Université de Liège - ULg > > Chimie médicale >]
Robe, Pierre mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Génétique générale et humaine >]
Delhalle, S. [> > > >]
Benoit, V. [> > > >]
Merville, Marie-Paule mailto [Université de Liège - ULg > Département de pharmacie > Chimie médicale >]
15-Oct-2000
Biochemical Pharmacology
60
8
1085-9
Yes (verified by ORBi)
International
0006-2952
[en] The role of nuclear factor (NF)-kappa B in the regulation of apoptosis in normal and cancer cells has been extensively studied in recent years. Constitutive NF-kappa B activity in B lymphocytes as well as in Hodgkin's disease and breast cancer cells protects these cells against apoptosis. It has also been reported that NF-kappa B activation by tumor necrosis factor (TNF)-alpha, chemotherapeutic drugs, or ionizing radiations can protect several cell types against apoptosis, suggesting that NF-kappa B could participate in resistance to cancer treatment. These observations were explained by the regulation of antiapoptotic gene expression by NF-kappa B. However, in our experience, inhibition of NF-kappa B activity in several cancer cell lines has a very variable effect on cell mortality, depending on the cell type, the stimulus, and the level of NF-kappa B inhibition. Moreover, in some experimental systems, NF-kappa B activation is required for the onset of apoptosis. Therefore, it is likely that the NF-kappa B antiapoptotic role in response to chemotherapy is cell type- and signal-dependent and that the level of NF-kappa B inhibition is important. These issues will have to be carefully investigated before considering NF-kappa B as a target for genetic or pharmacological anticancer therapies.
http://hdl.handle.net/2268/18485

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.